About Us

Epidarex invests in early-stage,
high growth life science and health technology companies
in under-ventured markets
within the UK and US.

Epidarex Provides Equity Capital to Young Companies, Including University Spin-outs

Our international management team has a track record of successfully partnering with scientists and entrepreneurs to develop highly innovative products for the global healthcare market. We leverage our extensive relationships, industry operating experience and a disciplined investment approach to add significant value to our portfolio companies and to generate strong returns on investment for our Limited Partners.

We believe in working closely with the management of our portfolio companies to more effectively translate their research into world class, commercially driven companies.

Epidarex’s global network includes investment professionals, scientists, industry executives, health practitioners, policy experts, regulatory advisors and business development leaders. This network contributes significantly to the growth and development of Epidarex’s portfolio companies. We place a particular emphasis on the importance of international business development. Epidarex’s global network includes leading Japanese, Korean, European and US corporations and financial institutions. These partners help provide an important bridge to key markets, thereby further supporting the international growth of Epidarex investees.

The Epidarex Team

Experienced Professionals

A. Sinclair Dunlop

Managing Partner

Kyparissia Sirinakis

Managing Partner

Elizabeth Roper Ph.D.

Partner

Peter Finan Ph.D.

Venture Partner

Terri Burke

Venture Partner

Henning Steinhagen Ph.D.

Venture Partner

Mary Canning Ph.D.

Principal

Daniel Marshall Ph.D.

Senior Associate

Aksana Labokha Ph.D.

Associate

Matthew Miessau

Analyst

Rachel Haynes

Operations Manager

Advisory Board

William Sellers, MD

Advisor

William Burns

Advisor

Frank Armstrong, MB ChB

Advisor

Jeani Delagardelle

Advisor

Paul Sekhri

Advisor